[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-349277-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-349277-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","harnessing-id1-as-a-biomarker-in-a-plasmid-reporter-system-for-cervical-cancer","Harnessing Id1 as a biomarker in a plasmid reporter system for cervical cancer","","Cervical cancer incidence has remained largely stagnant in the U.S. despite screening advances, motivating improved diagnostic strategies. This preclinical study evaluates a diagnostic plasmid that drives secreted embryonic alkaline phosphatase (SEAP) expression via the cancer-specific promoter sequence inhibitor of differentiation 1 (Id1). Using pId1-SEAP transfection, Id1–SEAP relationships were characterized in cervical cancer cell lines and human tissues with Western blot and immunohistochemistry, including timed transfections and xenograft analyses.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/harnessing-id1-as-a-biomarker-in-a-plasmid-reporter-system-for-cervical-cancer/349277/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/harnessing-id1-as-a-biomarker-in-a-plasmid-reporter-system-for-cervical-cancer/349277.png","ImageObject",300,407,{"name":42,"@type":43},"Mabel","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-10-29","2026-09-22",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",8,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"What diagnostic approach does the study evaluate for cervical cancer?","Question",{"text":63,"@type":64},"The study evaluates pId1-SEAP, a diagnostic plasmid designed to induce SEAP expression through control by the Id1 cancer-specific promoter sequence.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"How were Id1 and SEAP expression measured in the experiments?",{"text":68,"@type":64},"Id1 expression was established using Western blot and immunohistochemistry, and SEAP production was characterized after transfecting cervical cancer cells and related models with pId1-SEAP.",{"name":70,"@type":61,"acceptedAnswer":71},"What does the study suggest about Id1’s value as a biomarker?",{"text":72,"@type":64},"pId1-SEAP can transfect cervical cancer cells to produce SEAP proportionally to endogenous Id1 expression, supporting its potential use in further cervical cancer model studies and in distinguishing HPV infection states.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},349277,1790197219,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,111,114,119,122,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":107,"doc_module":4,"doc_module_name":25,"category_name":108,"show_sort_weight":109,"slug":110},7,"Healthcare",40,"healthcare",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":112,"slug":113},30,"research-report",{"id":115,"doc_module":4,"doc_module_name":25,"category_name":116,"show_sort_weight":117,"slug":118},9,"Religion & Spirituality",20,"religion-spirituality",{"id":117,"doc_module":4,"doc_module_name":25,"category_name":120,"show_sort_weight":117,"slug":121},"World Cup","world-cup",{"id":123,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":123,"slug":125},10,"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":97,"slug":129},19,"General","general",{"code":4,"msg":82,"data":131},{"doc_id":79,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":55,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":123,"language":139,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":140,"faqs":141,"seo_title":142,"seo_description":12,"update_tm":143,"read_time":144,"preview_page_count":33,"preview_urls":145},7971474920318,"https://ap-avatar.wpscdn.com/avatar/74000ee537e6b0ca360?x-image-process=image/resize,m_fixed,w_180,h_180&k=1788430171632181674","[www. nature.com/scientificreports](www. nature.com/scientificreports)  \nOPEN  \nHarnessing Id1 as a biomarker in a plasmid reporter system for cervical cancer  \nAbbigael V. Eli1,2, Benjamin B. Kasten1, Yolanda Hartman1, Akhilesh M. Wodeyar1, Sherin James1,2, KatiA. Turner3, Emily E. Helman4, Andrea G. Kahn5, Rebecca C. Arend3 & Jason M. Warram1􀀍  \nStagnancy often-year cervical cancer (CC) incidence in the U.S., despite screening advancements, suggests the need for new CC screening technologies. This study in preclinical CC models evaluated a diagnostic plasmid that induces expression of a reporter (secreted embryonic alkaline phosphatase, SEAP) through the control of cancer-specific promoter sequence (inhibitor of differentiation 1, Id1). The plasmid (pId1-SEAP) was used to transfect CC cells in vitro and characterize SEAP production based on Id1 expression. Western Blot and immunohistochemistry were used to establish Id1 expression in cell models and human tissues. Timed transfections in various conditions were used to correlate Id1 and SEAP expression. CC cell lines expressed increased normalized baseline Id1 (HeLa 3.0 ± 0.13, SiHa 2.9 ± 0.27, both P \u003C 0.0001) compared to non-cancer 3T3 fibroblasts (1.0 ± 0.0) . Normal cervical tissues had a mean Id1 staining value of 3E4 ± 3E4, while early-and late-stage CC tissues had increased mean Id1 staining (3E5 ± 1E5 P\u003C 0.0001 and 2E5 ± 1E5 P= 0.0002, respectively). HeLa and SiHa lines produced increased normalized SEAP (0.63 ± 0.25 and 0.50 ± 0.10, P \u003C 0.05) compared to 3T3 cells, both with pId1-SEAP (0.16 ± 0.058). As few as 12,500 pId1-SEAP transfected HeLa cells resulted in increased SEAP (3E4 ± 3E3 P= 0.004) compared to background (1E4 ± 4E2) . SiHa xenograft ex vivo tumor transfected with 25 µg/µL pId1-SEAP produced significantly greater SEAP (21.7 ± 8.6, P = 0.0003) relative to muscle transfected in the same conditions (0.94 ± 0.24). pId1-SEAP can transfect CC cells to produce SEAP proportionally to endogenous Id1 expression, demonstrating its potential for additional studies inCC models.  \nThe American Cancer Society estimates 13,360 new cases of cervical cancer will be diagnosed in the U.S. in 2025. However, over 90% of cervical cancer is preventable with vaccination against human papillomavirus (HPV) infection or with routine participation in early detection programs that screen for the presence of HPV infection or the presence of abnormal cervical cells. The five-year survival rate for localized cervical cancer is 91%, and regular participation in screening according to recommended guidelines increases the likelihood of detecting precancer or localized cervical cancer that can be treated and cured. Even with existing screening and prevention efforts, patients in rural and medically-underserved areas of the country are disproportionately diagnosed at later stages and consequently succumb to this preventable disease1. Cervical cancer incidence has not changed considerably within the past 10 years2 which suggests that current screening and prevention methods have reached their maximum efficacy and new efforts are needed to continue to decrease disease incidence. Current recommended screening efforts rely on detection of HPV DNA or abnormal cells in a prepared Pap cytology smear, both of which analyze cells collected from a cervical swab. HPV testing only indicates the presence of a current HPV infection, which could be transient and clear spontaneously without treatment or intervention3. In contrast, Pap cytology detects abnormal cells that could be malignant, alerting to the presence of possible precancerous conditions, such as low- or high-grade squamous intraepithelial lesions (LSIL, HSIL)4. While HPV testing is the most sensitive of current cervical cancer screening methods, it lacks specificity in younger populations due to its inability to distinguish between transient and persistent, transforming HPV infections5,6. Inhibitor of differentiation 1 (Id1) is a class V heli","cbCaigvKhmo3SpeZ","https://ap.wps.com/l/cbCaigvKhmo3SpeZ","pdf",1731043,"English","# Introduction\n## Rationale for improved cervical cancer screening\n# Plasmid reporter design and methods\n## pId1-SEAP transfection and reporter readout\n## Measuring Id1 expression in cells and tissues\n# Results\n## Baseline Id1 differences between cancer and non-cancer models\n## Correlation between Id1 levels and SEAP output\n# Discussion\n## Id1 as a target for distinguishing HPV infection states","[{\"question\":\"What diagnostic approach does the study evaluate for cervical cancer?\",\"answer\":\"The study evaluates pId1-SEAP, a diagnostic plasmid designed to induce SEAP expression through control by the Id1 cancer-specific promoter sequence.\"},{\"question\":\"How were Id1 and SEAP expression measured in the experiments?\",\"answer\":\"Id1 expression was established using Western blot and immunohistochemistry, and SEAP production was characterized after transfecting cervical cancer cells and related models with pId1-SEAP.\"},{\"question\":\"What does the study suggest about Id1’s value as a biomarker?\",\"answer\":\"pId1-SEAP can transfect cervical cancer cells to produce SEAP proportionally to endogenous Id1 expression, supporting its potential use in further cervical cancer model studies and in distinguishing HPV infection states.\"}]","Harnessing Id1 as a biomarker in a plasmid reporter system for cervical cancer | PDF",1790082573,25,[146,150,154,158],{"page_no":22,"url":147,"width":148,"height":149},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/11503ecb1d5d7f998a65830f9ff5394b.webp",983,1291,{"page_no":26,"url":151,"width":152,"height":153},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/518590bef42d3eb76c71ea44f060345d.webp",982,1290,{"page_no":30,"url":155,"width":156,"height":157},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/ede709f5610ac4dc1c91d27199f90fc6.webp",981,1289,{"page_no":33,"url":159,"width":160,"height":161},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/567cdc4338c4cae4fe37e651863358e2.webp",980,1287]